Eflapegrastim

Therapeutic indications

Eflapegrastim is indicated for:

Febrile neutropenia

Population group: only adults (18 years old or older)

Eflapegrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.

Limitations of use:

Eflapegrastim is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Eflapegrastim is contraindicated in the following cases:

History of serious allergic reactions to eflapegrastim, pegfilgrastim, or filgrastim

at least one of
Allergic reaction and additionally at least one of
Eflapegrastim
Pegfilgrastim

Filgrastim allergy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2023: ROLVEDON Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈